RMP Structure — Parts I Through VI

GVP Module V structures the RMP into six parts, and the sequence itself tells a story worth reading as a sequence rather than six independent sections: it moves from establishing what the product is and what its risks are, through what the organisation commits to doing about those risks, to how all of it gets communicated to the people who need to understand it, including patients themselves.

Part I, the Product Overview, is largely administrative — the substance, indication, dosage form, and regulatory status — establishing the basic context everything else in the document builds on. Part II, the Safety Specification, is where the actual risk picture gets defined: identified risks (confirmed associations), potential risks (plausible but not yet confirmed), and important missing information (populations or scenarios not yet adequately studied) — a lesson in its own right, covered next.

Part III, the Pharmacovigilance Plan, describes what monitoring activities — routine and, where the safety specification warrants it, additional — will actually be performed to characterise and track those risks going forward. Part IV, Post-Authorisation Efficacy Studies, is the structural outlier worth flagging explicitly here and again in its own lesson: unlike every other part, it addresses remaining uncertainty about efficacy, not safety, and confusing it with a safety-focused section is one of the more common structural misunderstandings newer PV professionals develop.

Part V, Risk Minimisation Measures, is where the plan moves from monitoring to active intervention — what will actually be done, beyond simply watching, to reduce the identified and potential risks in real-world practice, covered in depth in Lesson 9.4. And Part VI, the Public Summary, closes the document by translating all of the preceding technical content into plain language for patients and the public, which Lesson 9.10 treats as a genuinely distinct writing register from everything else in this course.